Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Beckermann on the Need for Biomarkers in Frontline RCC

August 10th 2022

Kathryn E. Beckermann, MD, PhD, discusses the need for biomarkers in frontline renal cell carcinoma.

Updated NCCN Guidelines Grant Tivozanib Category 1 Status for Pretreated RCC

August 10th 2022

The Kidney Cancer Treatment guidelines, housed within the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, have been revised, granting tivozanib Category 1 status as a subsequent therapy for patients with renal cell carcinoma who have received at least 2 prior lines of treatment.

FDA Accepts BLA for N-803 in BCG-Unresponsive Non–Muscle Invasive Bladder Cancer in Situ

August 1st 2022

The FDA has accepted for review a biologics license application for the IL-15 superagonist N-803 for the treatment of patients with Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer carcinoma in situ.

Adjuvant Nivolumab/Ipilimumab Fails to Meet DFS End Point in Localized RCC

August 1st 2022

The combination of nivolumab and ipilimumab failed to elicit a statistically significant improvement in disease-free survival compared with placebo as adjuvant treatment in patients with localized renal cell carcinoma who had undergone a full or partial removal of the kidney and were at moderate or high risk of relapse, failing to meet the primary end point of part A of the phase 3 CheckMate-914 trial.

Dr. Choueiri on the Use of Adjuvant Pembrolizumab in RCC

July 25th 2022

Toni Choueiri, MD, discusses the use of adjuvant pembrolizumab in renal cell carcinoma.

Pembrolizumab Post-Nephrectomy Extends Distant Metastasis-Free Survival, PFS2 in RCC

July 25th 2022

Toni K. Choueiri, MD, explains significant findings from the long-term efficacy analysis of the KEYNOTE-564 study and highlights the significance of these data for the field of RCC.

The Power of No, the Value of Yes

July 14th 2022

Brian I. Rini, MD, and Matthew Tucker, MD, sit down to discuss developing a career path and building a résumé, the value of writing review articles early in fellowship, the power of saying no, and the importance of saying yes.

ADCs and TKIs Plus Immunotherapy Signal the Future of Urothelial Carcinoma and RCC

July 12th 2022

Benjamin Garmezy, MD, discussed the positive trajectory of antibody-drug conjugates and immunotherapy in urothelial carcinoma, highlighting the importance of considering individual patient eligibility for treatments like first-line chemotherapy.

FDA Grants Fast Track Designation to Abelacimab for Thrombosis Associated With Cancer

July 11th 2022

The FDA has granted a fast track designation to abelacimab for the treatment of thrombosis associated with cancer.

Cabozantinib Plus Nivolumab/Ipilimumab Meets PFS End Point in Untreated Advanced RCC

July 11th 2022

The addition of cabozantinib to nivolumab and ipilimumab generated a significant improvement in progression-free survival vs nivolumab/ipilimumab alone as a first-line treatment for patients with previously untreated advanced intermediate- or poor-risk renal cell carcinoma, meeting the primary end point of the phase 3 COSMIC-313 trial.

Spiess Shares the Importance of Comprehensive, Multidisciplinary Care in Penile Cancer

July 11th 2022

Dr Spiess talks about taking part in an international consortium that seeks to establish a standard treatment for penile cancer, the ways shame interferes with diagnosis and treatment, and the complicated issues of gender and sexuality involved with this disease.

Dr. Jonasch on the Investigation of Belzutifan in ccRCC

July 8th 2022

Eric Jonasch, MD, discusses the investigation of belzutifan (Welireg) in clear cell renal cell carcinoma.

Penile Cancer Is Treatable, But the Armamentarium is Thin

June 28th 2022

Among men in the United States, incidence-based mortality is growing for penile cancer even though incidence remained consistent from 2000 to 2018.

Batiraxcept Combinations Under Further Investigation After Promising Efficacy Signals in Clear Cell RCC

June 26th 2022

Batiraxcept will continue to be investigated in combination with cabozantinib, plus in combination with cabozantinib and nivolumab and as a single agent, in patients with advanced or metastatic clear cell renal cell carcinoma in a phase 2 study.

Successful Treatment Options Expand to Earlier Lines in RCC and Urothelial Cancer

June 23rd 2022

Tian Zhang, MD, discusses the benefits of multidisciplinary collaboration, how to select the best agents for each patient, and how treatments such as radiation in RCC and bladder-sparing chemoradiation in urothelial cancer fit into the overall treatment paradigms for these diseases.

Unmet Needs in the Management of Advanced RCC

June 22nd 2022

Drs Alter and Diamond muse about the unmet needs in advanced RCC treatment.

Cabozantinib + Nivolumab Regimen in the Treatment of Advanced RCC

June 22nd 2022

A discussion on the role of the cabozantinib and nivolumab regimen in the treatment of advanced RCC.

Adjuvant and Neoadjuvant Treatments Chart New Course in Advanced RCC

June 17th 2022

A panel of kidney cancer experts discuss how therapeutic strategies in the neoadjuvant and adjuvant settings are affecting outcomes and how treatment selection in the first line has shifted approaches in the second and later lines of therapy.

Patient Profile Presentation: A 56-Year-Old Man with Clear Cell RCC

June 16th 2022

Robert Alter, MD, presents the patient profile of a 56-year-old man with clear cell renal cell carcinoma presenting with hip and leg pain.

Lee Lays Out Treatment Developments in Non–Clear Cell RCC

June 16th 2022

Dr Lee highlights treatment developments in non–clear cell renal cell carcinoma, emphasizes the need for precise classification of the histologic subsets of this disease, and discusses the investigation of cabozantinib plus nivolumab across stratified cohorts of non–clear cell renal cell carcinoma.